Pharmacognosy · Migraine Prevention · Fr. Pharmacopoeia List A

Feverfew

Tanacetum parthenium (Asteraceae) — a short perennial herb native to Asia Minor, now naturalized across uncultivated ground throughout Europe. Its marker compound, parthenolide, partially activates then desensitizes the TRPA1 pain channel, suppressing the neuropeptide release implicated in migraine attacks — making feverfew one of the most clinically studied botanicals for migraine prevention.

58 Primary Refs
8 Properties
Leaf Parts Used
✦ Researched
Last Updated August 2, 2026
Primary Source Wikiphyto · NCBI PubMed · The Lancet
Family Asteraceae
French Pharmacopoeia List A · Asteraceae

Biological Overview

Tanacetum parthenium is a short-lived perennial herb native to Asia Minor and now naturalized across uncultivated ground throughout Europe. It grows branched stems bearing deeply lobed, pinnately divided leaves, topped by loose clusters of daisy-like flower heads with yellow tubular centers and white ray florets.

HabitBranched Perennial Herb
Native RangeAsia Minor · Naturalized Europe
Parthenolide Content0.2–0.5% (aerial parts)
Regulatory StatusFr. Pharmacopoeia List A
Botanical Classification

Taxonomy & Identification

Latin Name
Tanacetum parthenium (L.) Schultz-Bip.
Synonym(s)
Chrysanthemum parthenium (L.) Pers.; Pyrethrum parthenium Sm.
Family
Asteraceae (Compositae)
Common Names
Feverfew, Grande Camomille, Partenelle
Parts Used
Aerial parts, flowering tops
Origin
Native to Asia Minor; naturalized across uncultivated ground in Europe
Ethnobotany & Traditional Use

History & Tradition

Feverfew's English name reflects a long folk reputation for calming fevers and head pain, but its use within structured phytotherapy is comparatively recent — the plant only entered rigorous clinical study in the latter half of the 20th century.

Feverfew's efficacy against migraine appears to have been recognized since antiquity, but it took until the 1980s for a randomized, double-blind trial by Murphy and colleagues to confirm it clinically — showing a significant reduction in migraine symptoms and recurrence frequency among the study's 72 volunteers, without serious side effects. 48

The French Pharmacopoeia lists the aerial part on its List A, and feverfew's phytochemical record includes a notable early observation: parthenolide, now considered central to the plant's action, is present in European-origin drug material but reported absent in feverfew grown in the Americas.

⚠ Parthenolide Content Varies by Origin

Parthenolide, the compound most consistently linked to feverfew's antimigraine activity, is reported present in European-sourced leaf but absent from material grown in the Americas — meaning origin and standardization matter more for feverfew than for most botanicals.

Timeline

Folk Reputation for Fevers & Headache

Pre-20th Century

Long used in traditional European herbalism for fevers and head pain, giving the plant its English common name.

Phytochemical Origin Discrepancy Noted

20th Century

Parthenolide was found present in European-origin feverfew but absent from American-grown material — an early clue to its active-compound profile.

Clinical Confirmation for Migraine

1980s

Murphy and colleagues' double-blind, placebo-controlled trial provided the first rigorous clinical confirmation of feverfew's antimigraine effect.

Mechanism & Regulatory Consolidation

2000s–Present

TRPA1-channel and NF-κB research clarified feverfew's mechanism, while the French Pharmacopoeia listed the aerial part on List A.

The Key Molecule

Parthenolide — Deep Dive

The sesquiterpene lactone behind feverfew's antimigraine reputation, and the compound used to standardize commercial products.

🧬

Sesquiterpene Lactone Structure

Parthenolide makes up roughly 0.2–0.5% of feverfew's aerial parts, alongside related lactones including epoxy-artemorin, canin, artecanin, and the seco-tanapartholides. 12

🎯

TRPA1 Partial Agonism

Parthenolide is a partial agonist of the transient receptor potential ankyrin 1 (TRPA1) channel, desensitizing it after an initial stimulation and defunctionalizing nociceptors. 13

🧠

CGRP Suppression

This TRPA1 pathway inhibits release of calcitonin gene-related peptide (CGRP) in the trigeminovascular system, suppressing nociceptive responses relevant to migraine. 13

⚗️

Origin-Dependent Standardization

A parthenolide content of roughly 0.2% is considered the traditional minimum efficacy threshold in dried-leaf preparations, which is why standardization to marker-compound content matters for this herb.

⚠ Not All Feverfew Is Equal

Parthenolide content varies by growing origin and processing.

Because parthenolide has been reported absent from American-grown feverfew, and can degrade with poor storage or processing, look for products that state a standardized parthenolide percentage rather than "feverfew leaf" alone.

Pharmaceutical Preparations

Parts Used & Available Forms

The aerial parts and flowering tops are used medicinally, prepared across three standardized forms.

Mother Tincture

Tincture of Pyrethrum parthenium (= Chrysanthemum parthenium), used at practitioner-directed dilution.

Mother Tincture

Standardized Plant Extract

Fresh-plant standardized extract (EPS) offering consistent parthenolide content batch to batch.

Standardized Extract

Dry Extract

Concentrated dry extract (marketed under names like Élusane), commonly used in migraine-prevention regimens.

Dry Extract

Clinical Dosimetry

Dosages

Migraine-prevention dosing reflects the EMA's cited regimens; duration and monitoring should be set by a qualified practitioner.

Form Dose Frequency Context Notes
Dried Leaf (Infusion) 2.5–5 g Daily Traditional use General traditional dosing for daily infusion.
CO2 Extract 50 mg 2× daily Migraine prevention (EMA) Cited by the EMA for migraine prophylaxis.
Dry Hydroalcoholic Extract 200 mg 1–2× daily Migraine prevention (EMA) Cited by the EMA for migraine prophylaxis.
Powder 200–260 mg 3× daily Migraine prevention (EMA) Roughly 100–600 mg per day in total.
Phytochemistry

Composition

Aerial-part and essential-oil composition only — no gemmotherapy (bud) fraction is documented for this species.

Aerial Parts — Primary Constituents

ParthenolideSesquiterpene lactone, primary marker compound 12
0.2–0.5%
Other Sesquiterpene LactonesEpoxy-artemorin, canin, artecanin, seco-tanapartholides A & B, reynosin, santamarine
Present
Essential OilRich in camphor and chrysanthenyl acetate 3
0.3–0.8% v/w
FlavonoidsWater-soluble flavones, lipophilic flavonols 3
Present

Essential Oil — Primary Constituents

CamphorDominant terpenoid component of the essential oil
Present
Chrysanthenyl AcetateCo-dominant ester component
Present
CampheneMonoterpene
Present
Germacrene DSesquiterpene
Present
para-CymeneAromatic monoterpene
Present

Plant Properties — Pharmacodynamics

Eight pharmacodynamic properties are documented for feverfew, anchored primarily in its parthenolide–TRPA1 pathway.

8 Properties Antimigraine Anti-inflammatory Clinical + Preclinical
💊

Analgesic

Extracts show antinociceptive activity in animal models, supporting feverfew's traditional use for pain. 456

🔥

Anti-inflammatory

Flavonoids and parthenolide both contribute anti-inflammatory activity, alongside inhibition of granulocyte degranulation. 2325

🧠

Antimigraine

Inhibits platelet aggregation and ADP/adrenaline-induced serotonin release, with parthenolide desensitizing the TRPA1 channel in the trigeminovascular system. 8910

🩸

Antiplatelet

Inhibits platelet aggregation and serotonin release induced by ADP or adrenaline, a mechanism proposed to underlie its antimigraine activity. 1112

🌀

Antispasmodic

Smooth-muscle antispasmodic action via an alpha-blocking effect, inhibiting contractions induced by serotonin and phenylephrine. 30

🛡️

Gastroprotective

Parthenolide shows gastroprotective activity via antioxidant, anti-inflammatory, and anti-apoptotic effects. 26

🫘

Nephroprotective

Phytosome-formulated parthenolide attenuates gentamicin-induced kidney toxicity in animal models and reduces cisplatin- and carbon-tetrachloride-induced renal damage. 272829

🧫

Anticancer / Pro-apoptotic

Parthenolide is a documented inducer of apoptosis, with anti-leukemic activity studied in chronic lymphocytic and acute myelogenous leukemia models. 323537

Clinical Applications

Clinical Indications

Feverfew's primary use is migraine prevention, with additional traditional indications for menstrual pain and a notable melatonin connection.

🧠
Migraine Prevention
Primary Indication
  • Prophylactic Use: Prevention of migraine attacks and associated headaches; recent literature reviews show supportive evidence without major safety concerns. 44
  • Clinical Confirmation: Murphy et al.'s 1988 double-blind trial found significant reduction in migraine symptoms and recurrence frequency among 72 volunteers, without serious side effects. 48
🩸
Menstrual & Obstetric Pain
Traditional Indication
  • Dysmenorrhea & Catamenial Migraine: Traditionally used for painful periods, catamenial migraine, and labor-related pain. 45
  • Endometriosis (mixed evidence): Parthenolide suppresses the inflammatory peritoneal environment in animal models, though effects may vary by dose and could worsen the condition in some contexts. 4647
🌙
Melatonin & Migraine Connection
Physiological Observation
  • Elevated Melatonin Content: Feverfew leaves contain notably elevated melatonin levels; researchers have proposed this contributes to migraine relief via melatonin rebalancing in migraineurs without aura. 51
⚠️
Use Considerations
Clinical Precautions
  • White Willow Combination: Improvement appears potentiated by combining feverfew with white willow bark, at roughly 300 mg of each. 1415
  • Pregnancy: Contraindicated — emmenagogue action, potentially abortifacient.
Pharmacodynamics

Mode of Action

Feverfew's antimigraine effect draws on several converging mechanisms, from platelet biology to direct ion-channel modulation.

🩸

Platelet & Serotonin Modulation

Inhibits platelet aggregation and ADP/adrenaline-induced serotonin release, a mechanism proposed by Heptinstall and colleagues to underlie feverfew's antimigraine effect. 4950

🧪

Thiol-Reactive Methylene Lactone

The methylene lactone group of feverfew's sesquiterpene lactones reacts with protein thiol groups, a proposed basis for its broad bioactivity across inflammatory and nociceptive pathways.

🎯

TRPA1 Desensitization

Parthenolide is a partial TRPA1 agonist, desensitizing the channel after initial stimulation and defunctionalizing nociceptors — suppressing CGRP release in the trigeminovascular system. 13

⚗️

Prostaglandin Synthesis Inhibition

Sesquiterpene lactones inhibit prostaglandin synthetase in vitro, blocking conversion of arachidonic acid to prostaglandins — a proposed basis for feverfew's use in dysmenorrhea. 202122

Comparative Analysis

Feverfew vs Butterbur

The two most clinically studied botanicals for migraine prevention, working through entirely different mechanisms.

Criterion Feverfew Butterbur
Mechanism TRPA1 desensitization, CGRP suppression, antiplatelet/serotonin modulation Petasin/isopetasin — anti-inflammatory and calcium-channel activity
Best Use Case Migraine prophylaxis; also dysmenorrhea and catamenial migraine Migraine prophylaxis specifically
Evidence Base Multiple double-blind RCTs, including Murphy 1988, plus Cochrane reviews Also studied in RCTs, though safety depends on extract processing
Safety Profile ⚠ Caution with anticoagulants/antiplatelets; contraindicated in pregnancy ⚠ Requires pyrrolizidine-alkaloid-free (PA-free) extract due to liver-toxicity risk of raw root
Typical Form Standardized dry extract, CO2 extract, or tincture Standardized PA-free root extract
Regulatory Status Fr. Pharmacopoeia List A Not covered by Fr. Pharmacopoeia List A; regulation varies by country

Bottom Line

Feverfew and butterbur are the two most clinically studied botanical options for migraine prevention, working through different mechanisms — feverfew via TRPA1/CGRP and platelet pathways, butterbur via anti-inflammatory and calcium-channel activity. Butterbur carries an added manufacturing requirement (PA-free extract) that feverfew does not, which is one reason feverfew remains the more widely available option.

Risk Profile

Safety & Interactions

Feverfew carries a well-defined precaution profile centered on anticoagulant interactions, CYP450 inhibition, and pregnancy status.

⚠ Genuine Risks Specific to This Plant

Read Before Using Feverfew

  • Anticoagulant & antiplatelet interaction: not recommended alongside anticoagulants or antiplatelet drugs due to a potential potentiation risk, including a documented interaction with warfarin. 52
  • Contraindicated in pregnancy: feverfew is emmenagogue and potentially abortifacient. 5557
  • Allergic dermatitis risk: all sesquiterpene lactones in feverfew can cause allergic dermatitis, and cytotoxicity has been suspected.
  • Moderate CYP450 inhibition: feverfew moderately inhibits CYP2C8, CYP1A2, CYP2D6, CYP2C9, and CYP3A4, which can affect metabolism of other drugs. 5354
✓ How to Use Feverfew More Safely

A Practical Safety Checklist

  1. Avoid if on blood thinners. Don't combine with anticoagulant or antiplatelet medication without medical supervision.
  2. Never during pregnancy. Avoid entirely due to emmenagogue and potential abortifacient action.
  3. Use caution while breastfeeding. Data on parthenolide transfer into breast milk is lacking.
  4. Watch for skin reactions. Stop use if allergic dermatitis develops — a known risk of sesquiterpene lactones.
  5. Mind other medications. Feverfew moderately inhibits several CYP450 enzymes that affect how other drugs are metabolized.
  6. Check the parthenolide content. Look for products standardized to at least ~0.2% parthenolide, the traditional efficacy threshold.
⚠️

Adverse Effects

  • Allergic Dermatitis: all sesquiterpene lactones in feverfew can cause contact dermatitis, with suspected cytotoxicity.
  • No P-glycoprotein Interaction: feverfew has not shown interaction with P-glycoprotein transport.
  • CYP450 Inhibition: moderate inhibition of CYP2C8, CYP1A2, CYP2D6, CYP2C9, and CYP3A4. 5354
🚫

Contraindications & Interactions

  • Anticoagulants/Antiplatelets: not recommended due to potentiation risk, including a documented interaction with warfarin. 52
  • Pregnancy: contraindicated — emmenagogue, potentially abortifacient. 555657
  • Breastfeeding: avoid, given lack of data on parthenolide transfer into breast milk.
Clinical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare provider before starting feverfew, particularly if pregnant, breastfeeding, taking anticoagulants, or taking other medications.
Common Questions

Frequently Asked Questions

What is feverfew used for?
Feverfew is used mainly for migraine prevention, and traditionally for painful periods, catamenial migraine, and labor-related pain.
How does feverfew work for migraines?
Its marker compound, parthenolide, partially activates then desensitizes the TRPA1 channel, suppressing release of CGRP in the trigeminovascular system, while also inhibiting platelet aggregation and serotonin release linked to migraine attacks.
What is parthenolide?
Parthenolide is a sesquiterpene lactone making up roughly 0.2–0.5% of feverfew's aerial parts. It's present in European-grown feverfew but reported absent in American-grown material, and a content of about 0.2% is considered the traditional efficacy threshold.
What is the typical feverfew dosage?
Traditional use is 2.5–5 g of dried leaf infusion daily. For migraine prevention, the EMA cites 50 mg of CO2 extract twice daily, 200 mg of dry hydroalcoholic extract once or twice daily, or 200–260 mg of powder three times daily (roughly 100–600 mg per day total).
Can I take feverfew with blood thinners?
It isn't recommended. Feverfew is not advised alongside anticoagulants or antiplatelet medication because of a potential potentiation risk, including a documented interaction with warfarin.
Is feverfew safe during pregnancy?
No. Feverfew is contraindicated in pregnancy, as it is considered emmenagogue and potentially abortifacient.
Does combining feverfew with white willow bark help?
Some research suggests migraine improvement is potentiated when feverfew is combined with white willow bark, at roughly 300 mg of each, though larger confirmatory trials are still needed.
Is feverfew better than butterbur for migraine prevention?
Both are among the most clinically studied botanicals for migraine prevention but work through different mechanisms. Feverfew acts via TRPA1/CGRP and platelet pathways, while butterbur requires a pyrrolizidine-alkaloid-free extract due to liver-toxicity concerns with the raw root — one reason feverfew remains more widely available.
Sources

Bibliography

1. Hendricks H, Anderson-Wildeboer Y, Engels G, Bos R, Woerdenbag HJ. The content of parthenolide and its yield per plant during the growth of Tanacetum parthenium. Planta Med. 1997;63(4):356–359. DOI: 10.1055/s-2006-957700↩
2. Fontanel D, Bizot S, Beaufils P. Dosage par CLHP du parthenolide contenu dans la grande camomille Tanacetum parthenium (L.) Schultz-Bip. Plantes méd phytothér. 1990;24(4):231–237.
3. Bruneton J. Pharmacognosie. Phytochimie. Plantes médicinales. Tec & Doc, Paris, 4th ed., 2009, p.765.↩
4. Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol. 1999;68(1-3):251–259.
PubMed: PMID 10624885 →↩
5. Parvin N, Asgari A. The analgesic effect of alcoholic extract of Tanacetum parthenium on pain in mice in formalin model. 2012;14:63–69.
6. Fereydouni M, Etemadi L, Borouk A. Analgesic effect of flower and leaf extracts of Tanacetum parthenium using formalin test in mice. Physiology and Pharmacology. 2001-2002;5(2):189–198.
7. Bukhari IA, Khan RA, Gilani AH, Shah AJ, Hussain J, Ahmad VU. The analgesic, anti-inflammatory and calcium antagonist potential of Tanacetum artemisioides. Arch Pharm Res. 2007;30(3):303–312.
8. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res. 1997;11(7):508–511.
9. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis — a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22(7):523–532.
PubMed: PMID 12230594 →
10. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention — a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25(11):1031–1041.
PubMed: PMID 16232154 →
11. WHO Monographs on Selected Medicinal Plants, Volume 2. World Health Organization. 2002.↩
12. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed). 1985;291(6495):569–573.
PubMed: PMID 3929876 →↩
13. Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain. 2013;154(12):2750–2758.
PubMed: PMID 23933184 →↩
14. Shrivastava R. Association de l'écorce de Saule et de la Grande Camomille: une alternative thérapeutique aux traitements de fond de la migraine. Doctoral thesis, Université Clermont Auvergne, 2020.↩
15. Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig. 2006;26(5):287–296.
PubMed: PMID 17163262 →↩
16. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia. 1998;18(10):704–708.
PubMed: PMID 9950629 →
17. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;(1):CD002286.
PubMed: PMID 14973986 →
18. Chen CF, Leung AY. Gene response of human monocytic cells for the detection of antimigraine activity of feverfew extracts. Can J Physiol Pharmacol. 2007;85:1108–1115.
PubMed: PMID 18066113 →
19. Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G. Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation. Cephalalgia. 2005;25(8):612–621.
PubMed: PMID 16033387 →
20. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40(10):743–745.
PubMed: PMID 2907548 →↩
21. Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet. 1980;2(8200):922–923.
PubMed: PMID 6107575 →↩
22. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40:743–745. (duplicate citation of ref 20 in source)↩
23. Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry. 1999;51(3):417–423.
PubMed: PMID 10382317 →↩
24. Williams CA, Hoult JR, Harborne JB, Greenham J, Eagles J. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry. 1995;38(1):267–270.
PubMed: PMID 7766058 →
25. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages. Biochem Biophys Res Commun. 1996;226(3):810–818.
PubMed: PMID 8831694 →↩
26. Shaik RA. Parthenolide alleviates indomethacin-induced gastric ulcer in rats via antioxidant, anti-inflammatory, and antiapoptotic activities. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(10):7683–7695.
PubMed: PMID 38703207 →↩
27. Albalawi RS, Binmahfouz LS, Hareeri RH, Shaik RA, Bagher AM. Parthenolide phytosomes attenuated gentamicin-induced nephrotoxicity in rats via activation of Sirt-1, Nrf2, OH-1, and NQO1 axis. Molecules. 2023;28(6):2741.
PubMed: PMID 36985711 →↩
28. Francescato HD, Costa RS, Scavone C, Coimbra TM. Parthenolide reduces cisplatin-induced renal damage. Toxicology. 2007;230(1):64–75.
PubMed: PMID 17156909 →↩
29. Mazani M, Mahmoodzadeh Y, Chinifroush Asl MM, Banaei S, Rezagholizadeh L, Mohammadnia A. Renoprotective effects of the methanolic extract of Tanacetum parthenium against carbon tetrachloride-induced renal injury in rats. Avicenna J Phytomed. 2018;8(4):370–379.
PubMed: PMID 30377595 →↩
30. Orona-Ortiz A, García-de la Cruz L, González-Soto I, et al. Inhibition of phenylephrine- or serotonin-induced rat aorta contractions by Mexican feverfew (Tanacetum parthenium). Latinoam Quim. 2018;46(2-3).↩
31. Thakkar JK, Sperelakis N, Pang D, Franson RC. Characterization of phospholipase A2 activity in rat aorta smooth muscle cells. Biochim Biophys Acta. 1983;750(1):134–140.
PubMed: PMID 6824708 →
32. Won YK, Ong CN, Shi X, Shen HM. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis. 2004;25(8):1449–1458.↩
33. Bhattacharya T, Dutta S, Akter R, et al. Role of phytonutrients in nutrigenetics and nutrigenomics perspective in curing breast cancer. Biomolecules. 2021;11(8):1176.
PubMed: PMID 34439842 →
34. Panieri E, Buha A, Telkoparan-Akillilar P, et al. Potential applications of NRF2 modulators in cancer therapy. Antioxidants (Basel). 2020;9(3):193.
PubMed: PMID 32106613 →
35. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol. 2008;46(2):129–135.
PubMed: PMID 18519227 →↩
36. Steele AJ, Jones DT, Ganeshaguru K, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia. 2006;20(6):1073–1079.
PubMed: PMID 16628188 →
37. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163–4169.
PubMed: PMID 15687234 →↩
38. Quy AS, Li X, Male L, Stankovic T, Agathanggelou A, Fossey JS. Aniline-containing derivatives of parthenolide: synthesis and anti-chronic lymphocytic leukaemia activity. Tetrahedron. 2020;76(48):131631.
PubMed: PMID 33299257 →
39. Li X, Payne DT, Ampolu B, et al. Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia. Medchemcomm. 2019;10(8):1379–1390.
PubMed: PMID 32952998 →
40. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr. 2000;3(4A):509–514.
PubMed: PMID 11276299 →
41. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention. Neurology. 2012;78(17):1346–1353.
PubMed: PMID 22529203 →
42. Rajapakse T, Davenport WJ. Phytomedicines in the treatment of migraine. CNS Drugs. 2019;33(5):399–415.
PubMed: PMID 30627973 →
43. Levin M. Herbal treatment of headache. Headache. 2012;52(Suppl 2):76–80. PMID 23030536.
44. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;(4):CD002286.↩
45. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacogn Rev. 2011;5(9):103–110.
PubMed: PMID 22096324 →↩
46. Takai E, Taniguchi F, Nakamura K, Uegaki T, Iwabe T, Harada T. Parthenolide reduces cell proliferation and prostaglandin E2 in human endometriotic stromal cells and inhibits development of endometriosis in the murine model. Fertil Steril. 2013;100(4):1170–1178.
PubMed: PMID 23876538 →↩
47. Song H, Huang Y, Peng Q, Xue C, Zhou YF. Effects of parthenolide on estradiol-synthesizing enzyme, ER isoforms and VEGF in human endometriotic stromal cells. Zhonghua Fu Chan Ke Za Zhi. 2019;54(7):464–469.
PubMed: PMID 31365959 →↩
48. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2(8604):189–192.
PubMed: PMID 2899663 →↩
49. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet. 1985;1(8437):1071–1074.
PubMed: PMID 2860288 →↩
50. Heptinstall S. Feverfew — an ancient remedy for modern times? J R Soc Med. 1988;81(7):373–374.
PubMed: PMID 3045310 →↩
51. Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet. 1997;350(9091):1598–1599.
PubMed: PMID 9393344 →↩
52. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57(13):1221–1227.
PubMed: PMID 10902065 →↩
53. Williamson EM, Driver S, Baxter K. Stockley's Herbal Medicines Interactions: A Guide to the Interactions of Herbal Medicines. Pharmaceutical Press, 2013.↩
54. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using LC/MS and automated online extraction. Rapid Commun Mass Spectrom. 2004;18(19):2273–2281.
PubMed: PMID 15384148 →↩
55. Barnes LAJ, Barclay L, McCaffery K, Aslani P. Complementary medicine products used in pregnancy and lactation. BMC Complement Altern Med. 2018;18(1):229.
PubMed: PMID 30064415 →↩
56. Ahmed M, Hwang JH, Choi S, Han D. Safety classification of herbal medicines used among pregnant women in Asian countries: a systematic review. BMC Complement Altern Med. 2017;17(1):489.
PubMed: PMID 29137614 →↩
57. Ernst E. Herbal medicinal products during pregnancy: are they safe? BJOG. 2002;109(3):227–235.
PubMed: PMID 11950176 →↩

Additional Sources

Groenewegen WA, Knight DW, Heptinstall S. Progress in the medicinal chemistry of the herb feverfew. Prog Med Chem. 1992;29:217–238.
PubMed: PMID 1475370 →